For immunochemical detection of cytokeratin 5 and cytokeratin 6
Technical Support & Resources

Visit our FAQ

Contact Us

Toll Free Phone (USA and Canada Only): (888) 526-5351
Direct Phone: (734) 975-3888

Request Technical Support

Technical Support Request

To streamline the process attach the appropriate questionnaire to your inquiry.

Download IHC QuestionnaireDownload WB Questionnaire

View Our Privacy Statement for details on how we use and protect your data. In addition, this site is protected by hCaptcha and its Privacy Policy and Terms of Service apply.

Cytokeratin 5/Cytokeratin 6 (C-Term) Rabbit Monoclonal Antibody (Clone RM341)

Item No. 32307

Product Insert (PDF)Safety Data Sheet (SDS) (PDF)
Technical Information
Synonyms
  • CK5/CK6
  • Keratin, Type II Cytoskeletal 5/6
  • Keratin 5/Keratin 6
  • KRT5/KRT6
Immunogen
Peptide from the C-terminal region of human cytokeratin 5
Clone Designation
RM341
Formulation (Request formulation change)
100 µl of Protein A-affinity purified monoclonal antibody
Storage Buffer
PBS with 50% glycerol, 1% BSA, and 0.09% sodium azide
Host
Rabbit
Isotype
IgG
Applications
IHC, WB
Cross Reactivity
(+) Cytokeratin 5(+) Cytokeratin 6
Species Reactivity
(+) Human
Shipping & Storage Information
Storage
-20°C
Shipping
Wet ice in continental US; may vary elsewhere
Recommended Products

Certificates of Analysis & Batch Specific Data

Provide batch numbers separated by commas to download or request available product inserts, QC sheets, certificates of analysis, data packs, and GC-MS data.

    100 µl

    $418

    Add
    Cayman Chemical
    Visit Our Cancer Resource Center
    Find Tools & Resources to Study the Hallmarks of Cancer
    • Cancer cell signaling & regulation
    • Cancer metabolism
    • Tumor microenvironment
    EXPLORE NOW
    Product Description

    Cytokeratin 5 (CK5) and CK6 are type II intermediate filament proteins.1,2 They are each composed of a central rod containing four α-helical domains, which are important for self-assembly, and non-helical head and tail domains at the N- and C-termini, respectively. CK5 is expressed in basal keratinocytes in the epidermis and is an integral component of the epithelial cell cytoskeleton.3 It dimerizes with the type I epithelial intermediate filament protein CK14 via heptad repeats in the central rod domain to form a network of filament bundles throughout the cytoplasm.4,1 CK6 expression is restricted to ectoderm-derived epithelial appendages, such as hair follicles, nails, and teeth, but is induced at sites of wound injury and persists until barrier function is restored and the wound is closed.2 CK5 and CK6 are associated with poor prognosis in patients with high-grade serous ovarian carcinoma or triple-negative breast cancers.5,6 Cayman’s Cytokeratin 5/Cytokeratin 6 (C-Term) Rabbit Monoclonal Antibody (Clone RM341) can be used for immunohistochemistry (IHC) and Western blot (WB) applications.

    WARNING This product is not for human or veterinary use.

    References & Product Citations
    Product Description References

    1. Gu, L.-H., and Coulombe, P.A. Keratin function in skin epithelia: A broadening palette with surprising shades. Curr. Opin. Cell Biol. 19(1), 13-23 (2007).

    2. Wang, F., Chen, S., Liu, H.B., et al. Keratin 6 regulates collective keratinocyte migration by altering cell–cell and cell–matrix adhesion. J. Cell Biol. 217(12), 4314-4330 (2018).

    3. Atkinson, S.D., McGilligan, V.E., Liao, H., et al. Development of allele-specific therapeutic siRNA for keratin 5 mutations in epidermolysis bullosa simplex. J. Invest. Dermatol. 131(10), 2079-2086 (2011).

    4. Chan, Y.M., Yu, Q.C., LeBlanc-Straceski, J., et al. Mutations in the non-helical linker segment L1-2 of keratin 5 in patients with Weber-Cockayne epidermolysis bullosa simplex. J. Cell Sci. 107(Pt 4), 765-774 (1994).

    5. Taube, E.A., Denkert, C., Sehouli, J., et al. Cytokeratin 5/6 expression, prognosis and association with ER-α in high-grade serous ovarian carcinoma. Hum. Pathol. 67, 30-36 (2017).

    6. Inanc, M., Ozakan, M., Karaca, H., et al. Cytokeratin 5/6, c-Met expressions, and PTEN loss prognostic indicators in triple-negative breast cancer. Med. Oncol. 31(1), 801 (2013).